Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) have been given a consensus recommendation of “Hold” by the five ratings firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is C$23.33.

VRX has been the subject of several analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a C$26.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, May 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, June 29th. Finally, TD Securities boosted their price objective on Valeant Pharmaceuticals Intl to C$26.00 and gave the stock a “hold” rating in a research report on Wednesday, July 12th.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Receives Consensus Recommendation of “Hold” from Brokerages” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/10/valeant-pharmaceuticals-intl-inc-vrx-receives-consensus-recommendation-of-hold-from-brokerages.html.

In other news, Director Schutter Richard Urbain De bought 4,900 shares of the business’s stock in a transaction on Monday, August 21st. The stock was purchased at an average cost of C$14.35 per share, for a total transaction of C$70,315.00. Also, Director John Paulson sold 24,700 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total value of C$362,102.00.

Shares of Valeant Pharmaceuticals Intl (TSE VRX) opened at 16.52 on Friday. Valeant Pharmaceuticals Intl has a 12-month low of $11.20 and a 12-month high of $37.70. The stock has a 50 day moving average price of $18.61 and a 200 day moving average price of $17.34. The firm’s market capitalization is $5.76 billion.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (TSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.